An IMS Health report considers the rate of price declines when brand drugs lose their patent protection.
Research published in JAMA describes trends in the use of prescription drugs in the United States.
We continue our review of the 2015-16 drug benefit report, looking at utilization management, network design and other issues.
The 2015-2016 Prescription Benefit Management Institute report on drug benefits reveals useful information about design and cost trends.
The drug manufacturers trade association does a wonderful job of providing a rationalization for exorbitant pricing of medications, too bad it has no basis in moral or economic reality.
A report from the IMS Institute for Healthcare Informatics looks at the effect of pharmacy deductibles on medication adherence.
Specialty drug costs have gotten a lot of attention, but more concerning is some ways is the recent surge in prices of many generic drugs.
A study in Health Affairs finds that greater prescription drug use among Medicaid beneficiaries is associated with a modest reduction in overall spending.
HHS releases guidance on the operation of the controversial 340B drug pricing program, designed to address uncertainties and concerns.